SureTrader Nadex Advertisement
Home > Boards > US Listed > Biotechs >

Alimera Sciences (ALIM)

Add ALIM Price Alert      Hide Sticky   Hide Intro
Moderator: mick
Search This Board: 
Last Post: 2/27/2017 8:08:49 AM - Followers: 42 - Board type: Free - Posts Today: 0

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals.
The Company focuses on diseases affecting the back of the eye, or retina. The Company's commercial product is ILUVIEN, which has been developed to
treat diabetic macular edema (DME). ILUVIEN has received marketing authorization in the United States, Austria, Belgium, the Czech Republic, Denmark,
Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom.
In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and
did not have a rise in intraocular pressure (IOP). In the EU countries, it is indicated for the treatment of vision impairment associated with DME.


Fox Business News interview with the CEO accounted for the news. 

FDA approves new diabetes implant 
Apr. 21, 2016 - 3:25 - Alimera Sciences CEO Dan Myers on a new diabetes implant that treats macular degeneration.

Retinal Vein Occlusion (RVO)

ILUVIEN® Patent Notices

Please see the following table for U.S. Patents covering ILUVIEN®. The absence of a U.S. Patent number as associated with ILUVIEN does not constitute a waiver of our patent, trademark, or other intellectual property rights concerning that product.



ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg

U.S. 6,217,895

U.S. 6,375,972

U.S. 6,548,078

U.S. 8,252,307

U.S. 8,574,659

U.S. 8,871,241

Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company is developing ILUVIEN, an intravitreal insert in phase-3 clinical trials for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN insert designed to be inserted into the patient's eye to release a daily dose of fluocinolone acetonide over an anticipated period of 24 to 36 months. The company also conducts phase-2 clinical trials on ILUVIEN for the treatment of the dry form of age-related macular degeneration (AMD), the wet form of AMD, and retinal vein occlusion. In addition, it conducts testing on two classes of nicotinamide adenine dinucleotide phosphate oxidase inhibitors. Further, the company develops ILUVIEN inserter, a custom insertion system for ILUVIEN. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Alimera Sciences Inc. is based out of Alpharetta, GA and has some 132 employees.

Officers and directors

Richard S. Eiswirth Jr.   President, Chief Financial Officer
C. Daniel Myers   Chief Executive Officer, Director
Kenneth E Green Ph.D.   Senior Vice President, Chief Scientific Officer
David R Holland   Senior Vice President - Sales and Marketing
Philip Ashman   Senior Vice President, European Managing Director
David Burke   Vice President
Mark J. Brooks   Independent Director
Brian K. Halak Ph.D.   Independent Director
James R. Largent   Independent Director
Peter J. Pizzo III   Independent Director

Stonegate Capital Partners Initiates Coverage on Alimera Sciences
ACCESSWIRE via CMTX - Wed Apr 27, 8:02AM CDT


Alimera Sciences Reports Record Fourth Quarter and Full Year 2015 Financial Results
Mar 2, 2016

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ALIM News: Alimera Sciences to Report Fourth Quarter 2016 Financial Results on March 1, 2017 02/23/2017 11:24:03 AM
ALIM News: Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for IluvienĀ® in Canada 02/22/2017 08:00:00 AM
ALIM News: Statement of Ownership (sc 13g) 02/14/2017 06:11:52 PM
ALIM News: Amended Statement of Ownership (sc 13g/a) 02/14/2017 05:43:53 PM
ALIM News: Amended Statement of Ownership (sc 13g/a) 02/14/2017 03:02:00 PM
#853  Sticky Note Alimera Sciences and Knight Therapeutics Announce Filing of mick 02/22/17 08:47:22 AM
#862   Lol mikekrane 02/27/17 08:08:49 AM
#861   You know the zero's Lol. CarlCarlMcB 02/27/17 08:07:55 AM
#860   your here? i guess i dont need to mikekrane 02/23/17 08:16:54 AM
#859   Downward trend .0001 CarlCarlMcB 02/23/17 05:50:16 AM
#858   Hey guys havent folowed this one in a Zack2000 02/22/17 09:00:28 PM
#857   Timber CarlCarlMcB 02/22/17 02:02:19 PM
#856   Hey why so quiet today? rnoutlaw21 02/22/17 01:50:50 PM
#855   ALIM News: Alimera Sciences and Knight Therapeutics Announce mick 02/22/17 12:08:43 PM
#854   Alimera Sciences, In (ALIM) mick 02/22/17 12:08:34 PM
#853   Alimera Sciences and Knight Therapeutics Announce Filing of mick 02/22/17 08:47:22 AM
#852   Payday is coming. UserBob 02/22/17 12:43:48 AM
#851   Oh, I know I'm just messing around too, rnoutlaw21 02/21/17 08:58:58 PM
#850   I'd recommend you stop wasting energy on this salgovernale69 02/21/17 08:30:43 PM
#849   Co has over $30m in cash. rnoutlaw21 02/21/17 05:16:57 PM
#848   Co looking for money! CarlCarlMcB 02/21/17 05:12:08 PM
#847   Who will get the last laugh. .01 CarlCarlMcB 02/21/17 05:11:38 PM
#846   Hahahaha. Check back next week. You're rnoutlaw21 02/21/17 05:10:04 PM
#845   Debt . Lower we go . CarlCarlMcB 02/21/17 05:05:54 PM
#844   MM's tested supply today, very low volume selling rnoutlaw21 02/21/17 05:03:35 PM
#843   Going below a dollar. CarlCarlMcB 02/21/17 04:58:04 PM
#842   I don't get it? Are you short, just rnoutlaw21 02/21/17 10:27:58 AM
#841   Yep CarlCarlMcB 02/21/17 09:44:51 AM
#840   You posting on the right ticker? rnoutlaw21 02/21/17 09:41:44 AM
#839   Timber CarlCarlMcB 02/21/17 08:10:29 AM
#838   Look at the action today too, it can't rnoutlaw21 02/16/17 02:19:20 PM
#837   You do realize this is currently over 80% rnoutlaw21 02/16/17 02:10:44 PM
#836   .25 CarlCarlMcB 02/16/17 12:58:26 PM
#835   Timber !!! CarlCarlMcB 02/03/17 12:07:10 PM
#833   Paul Bunyan speaks again north40000 01/26/17 05:50:59 PM
#831   Yep head fake! .0001 CarlCarlMcB 01/26/17 08:26:35 AM
#830   It looks like the CEO and CSO recently bbhuey 01/26/17 08:25:06 AM
#829   Timber. CarlCarlMcB 01/26/17 06:16:49 AM
#828   Does anyone know when earnings are due Out bbhuey 01/24/17 06:00:35 PM
#827   .0001 CarlCarlMcB 01/20/17 03:43:58 AM
#826   Looking forward to next earnings report. Hopefully Norm 01/14/17 06:36:27 PM
#825   Yes, PPS target $4 end of year!! Backdraft4u 01/14/17 02:51:43 PM
#824   To the moon! UserBob 01/12/17 09:35:09 PM
#823   Why are up more than 12%. What happened?? pennies from heaven 01/10/17 11:40:10 AM
#822 mick 01/10/17 10:15:12 AM
#821   Timber CarlCarlMcB 01/10/17 09:32:22 AM
#820   Alimera Sciences, In (ALIM) mick 01/07/17 12:32:04 PM
#819   Okay !!! .25 ! CarlCarlMcB 01/07/17 12:21:22 PM
#818   Alimera Sciences, In (ALIM) mick 01/04/17 12:31:34 PM
#817   ALIM News: Statement of Changes in Beneficial Ownership mick 01/04/17 12:31:10 PM
#816   1.02 soon CarlCarlMcB 01/04/17 11:43:53 AM
#815   Falling knife! CarlCarlMcB 01/04/17 08:33:17 AM
#814   Why are you so vested in AlIMs failure? UserBob 01/04/17 08:30:09 AM
#813   Tic tock ! .01 CarlCarlMcB 01/04/17 07:51:32 AM
#812   Alimera Sciences, In (ALIM) mick 01/03/17 09:35:04 PM
#811   Grab a parachute!!! ! Free fall CarlCarlMcB 01/03/17 08:22:23 PM